Why the study?
The net benefit of PCI in patients with CKD is less well established than in the general population, despite a high and increasing prevalence of comorbid CAD and CKD.
How can outcomes of percutaneous coronary intervention be optimized in patients with chronic kidney disease?
How can outcomes of percutaneous coronary intervention be optimized in patients with chronic kidney disease?
Optimizing PCI outcomes in patients with CKD involves pre-procedural preparation, intra-procedural contrast reduction and radial access, and personalized post-procedural antithrombotic therapy.
Percutaneous coronary intervention (PCI) is one of the most common procedures performed in medicine. However, its net benefit among patients with chronic kidney disease (CKD) is less well established than in the general population. The prevalence of patients suffering from both CAD and CKD is high, and is likely to increase in the coming years. Planning the adequate management of this group of patients is crucial to improve their outcome after PCI. This starts with proper preparation before the procedure, the use of all available means to reduce contrast during the procedure, and the implementation of modern strategies such as radial access and drug-eluting stents. At the end of the procedure, personalized antithrombotic therapy for the patient's specific characteristics is advisable to account for the elevated ischemic and bleeding risk of these patients.
No takes yet. Share an insight, caveat, or question.
Caracciolo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: